Sionna Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 4/100
What the filing says
Michael Cloonan (CEO) and Elena Ridloff (CFO) certified the June 30, 2026 quarterly report on August 6, 2026 per Sarbanes-Oxley requirements. Both officers affirmed that financial statements fairly present the company's condition and results, disclosure controls are effective, and no material weaknesses or fraud were identified in internal controls.
Why this rating
Routine quarterly SOX certifications; boilerplate attestation. No material facts, changes, or deficiencies disclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.